( - Aggregate Benefit over Placebo Larger...)Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy,Health

SAN FRANCISCO and WASHINGTON, June 11, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that the benefits of Dimebon over placebo in its double-blind, placebo-controlled Phase 2 study in mild-to- moderate Alzheimer's disease were statistically significant on all five study endpoints at 12 months. Importantly, on every endpoint studied, the benefits of Dimebon over placebo at one year were stable or greater when compared to benefits at six months. Dimebon patients were stabilized over the one year study period, meaning that their level of function was preserved for a full year on all five endpoints. The endpoints spanned all of the most frequently studied aspects of Alzheimer's disease: cognition, overall clinical function, activities of daily living, and behavioral problems. Dimebon was well tolerated throughout the entire one-year treatment period.

On the study's primary endpoint, the ADAS-cog, Dimebon caused an improvement over placebo of 6.9 points at one year (observed case analysis; p<0.0001). On the global function endpoint used in this study, the CIBIC- plus, Dimebon's benefit over placebo was 0.8 points at 12 months (observed case analysis; p=0.006). Global function improved or remained stable in 69 percent of treated Alzheimer's disease patients after one year of Dimebon therapy. The ADAS-cog and the CIBIC-plus are the two endpoints the U.S. Food and Drug Administration has used to approve all currently marketed drugs for mild-to-moderate Alzheimer's disease.

Dimebon produced an aggregate benefit over placebo in this study that was larger at 12 months than at six. After a year of treatment Dimebon's benefit over placebo was greater than six-month levels on the ADAS-cog (6.9 points vs. 4.0 points), the CIBIC-plus (0.8 points vs. 0.6 points), and the ADCS-ADL (5.2 points vs. 2.9 points); however, only th
'"/>